After @ months , we found no significant differences between the omega-@ and placebo groups in the number of patients with decreased ALT by @ times the ULN ( @ vs @ ) or in median ( IQR ) ALT activity ( @ -LSB- @-@ -RSB- U/L vs @ -LSB- @-@ -RSB- U/L ) , liver hyperechogenicity , insulin resistance , or serum lipid levels .